Format

Send to

Choose Destination
Trends Cardiovasc Med. 2016 Oct;26(7):585-95. doi: 10.1016/j.tcm.2016.03.011. Epub 2016 Mar 31.

Digoxin: The good and the bad.

Author information

1
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; Institute of Cardiovascular Science, University College London, London, UK.
2
Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; Monash Centre of Cardiovascular Research & Education in Therapeutics, Monash University, Melbourne, Australia. Electronic address: d.kotecha@bham.ac.uk.

Abstract

After 230 years of use, digitalis remains an important and useful therapy for patients with atrial fibrillation, heart failure, and the 30-50 % of patients with both conditions. Although the combination of positive inotropic activity with negative chronotropic effects has been shown to reduce hospital admissions in heart failure, there is a distinct lack of robust trial data, particularly in patients with atrial fibrillation. We recently performed a comprehensive meta-analysis of all digoxin studies and demonstrated a neutral effect on mortality. This contradicts prior observational data that overlook the fact that digitalis is usually given as second-line therapy to the sickest patients. Use of these agents in clinical practice should take account of appropriate dose, serum concentration, drug interactions, and potential side effects. The aim of this review is to evaluate the evidence base for cardiac glycosides and provide a pragmatic guide to their advantages and disadvantages.

KEYWORDS:

Atrial fibrillation; Cardiac glycoside; Digoxin; Heart failure; Hospitalization; Mortality; Outcomes.

PMID:
27156593
DOI:
10.1016/j.tcm.2016.03.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center